Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Brief Summary: The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2
B: Arm Label: A (experimental group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Capecitabine, Drug: Trastuzumab | Arm Label: B (control group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A (experimental group) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): A (experimental group), B (control group)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E7389 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's Choice | Intervention Type: DRUG; Name: E7389; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Physician's Choice; Assigned to Arm(s): 2
D: Arm Label: Epi-CMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-CMF; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Accelerated Epi-Capecitabine, Epi-Capecitabine | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine

Answer: A